ConCallIQ
Go Pro
Home › Sunpharma › Revenue History

Sunpharma Revenue History — Quarter by Quarter

Sunpharma's revenue moved from ₹11,941 Cr in Q1 FY24 to ₹15,469 Cr in Q3 FY26, a 29.5% change over 11 quarters. The table keeps each quarter linked back to the underlying earnings page.

Revenue by Quarter

QuarterRevenue (₹ Cr)YoY Change
Q3 FY26₹15,469 Cr+15.1%
Q2 FY26₹14,405 Cr+8.6%
Q1 FY26₹13,786 Cr+10.1%
Q4 FY25₹12,959 Cr+8.5%
Q3 FY25₹13,675 Cr+10.5%
Q2 FY25₹13,264 Cr+10.5%
Q1 FY25₹12,653 Cr+6.3%
Q4 FY24₹11,983 Cr+10.1%
Q3 FY24₹12,381 Cr+9.5%
Q2 FY24₹12,192 Cr+11%
Q1 FY24₹11,941 Cr+10.7%

What management said about revenue

G

Q3 FY26 · Semaglutide launch in India on patent expiry

Sun Pharma plans to launch generic semaglutide in India on day one of patent expiry for both chronic weight management and type 2 diabetes, under brands NovelTreat and SemaTrinity.

G

Q2 FY26 · R&D spend at lower end of 6-8% of sales

Management expects full-year R&D spend to be at the lower end of the guided 6-8% range.

G

Q2 FY26 · Unloxcyt launch in H2 FY26

Unloxcyt remains on track for US launch in the second half of FY26, with sales force already in place.

G

Q2 FY26 · Ilumya psoriatic arthritis filing in H2 FY26

Sun Pharma plans to file Ilumya for psoriatic arthritis indication in the second half of FY26.

G

Q1 FY26 · ILUMYA PsA filing by end of CY2025

Sun Pharma plans to file for psoriatic arthritis indication for ILUMYA before end of calendar year 2025.

G

Q4 FY25 · FY26 revenue growth: mid-to-high single digit

Management expects consolidated top-line growth of mid-to-high single digits for FY2026.

G

Q4 FY25 · R&D spend guidance: 6%-8% of sales

FY2026 R&D spend expected to be 6%-8% of sales.

G

Q4 FY25 · Leqselvi launch in Q2 FY26

Leqselvi to be launched in the US in the second quarter of FY2026.

G

Q3 FY25 · FY25 R&D spend to be less than 7% of sales

Due to delays in clinical trial initiation, R&D expenditure for FY25 is expected to be below the earlier guidance of 7% of sales.

G

Q3 FY25 · Specialty sales growth to normalize after Q3 inventory build

Q3 specialty sales benefited from inventory build at a partner; next quarter sales are expected to be lower excluding milestones.

G

Q2 FY25 · R&D spend to be 7-8% of sales for FY25

R&D spend for FY25 is expected to be in the range of 7-8% of sales, down from earlier guidance of 8-10%, due to delays in clinical studies.

G

Q2 FY25 · Ilumya PsA Phase III data expected H2 CY2025

Phase III data for Ilumya in psoriatic arthritis is expected in the second half of calendar year 2025, with launch shortly after approval.